- Author:
Lingyun WANG
1
;
Rongzeng HAO
1
;
Yang YANG
1
;
Yajun LI
1
;
Bingzhou LU
1
;
Yuhan MAO
1
;
Yue ZHANG
1
;
Zhenli GONG
1
;
Yanhong LIU
1
;
Meng QI
2
;
Yi RU
1
;
Haixue ZHENG
1
Author Information
- Publication Type:Journal Article
- Keywords: Chinese hamster ovarian (CHO) cells; Seneca virus A; antiviral activity; expression and purification of protein; porcine interferon γ
- MeSH: Swine; Animals; Cricetinae; Interferon-gamma/pharmacology*; Cricetulus; CHO Cells; Sincalide; Recombinant Proteins/pharmacology*; Antiviral Agents/pharmacology*
- From: Chinese Journal of Biotechnology 2023;39(12):4784-4795
- CountryChina
- Language:Chinese
- Abstract: The aim of this study was to produce recombinant porcine interferon gamma (rPoIFN-γ) by Chinese hamster ovarian (CHO) cells expression system and to analyze its antiviral activity. Firstly, we constructed the recombinant eukaryotic expression plasmid pcDNA3.1-PoIFN-γ and transfected into suspension cultured CHO cells for secretory expression of rPoIFN-γ. The rPoIFN-γ was purified by affinity chromatography and identified with SDS-PAGE and Western blotting. Subsequently, the cytotoxicity of rPoIFN-γ was analyzed by CCK-8 test, and the antiviral activity of rPoIFN-γ was evaluated using standard procedures in VSV/PK-15 (virus/cell) test system. Finally the anti-Seneca virus A (SVA) of rPoIFN-γ activity and the induction of interferon-stimulated genes (ISGs) and cytokines were also analyzed. The results showed that rPoIFN-γ could successfully expressed in the supernatant of CHO cells. CCK-8 assays indicated that rPoIFN-γ did not show cytotoxicity on IBRS-2 cells. The biological activity of rPoIFN-γ was 5.59×107 U/mg in VSV/PK-15 system. Moreover, rPoIFN-γ could induced the expression of ISGs and cytokines, and significantly inhibited the replication of SVA. In conclusion, the high activity of rPoIFN-γ was successfully prepared by CHO cells expression system, which showed strong antiviral activity on SVA. This study may facilitate the investigation of rPoIFN-γ function and the development of novel genetically engineered antiviral drugs.